News
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...
With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...
Although Novo was first to market with Wegovy and its sister ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.
5h
Zacks Investment Research on MSNLilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...
Major benchmarks are down this year amid concerns about import tariffs and their impact on economic growth. The stock market may not seem like the ... evaluating the safety and efficacy of Zepbound ...
Now that trade deals are getting done, here's why this out-of-favor stock-market strategy may shine.
The U.S. and China, after trade talks in Geneva, agreed to cut tariffs on each other by 115 percentage points, for at least 90 days. Treasury Secretary Scott Bessent further added that talks on ...
Those projections include the impact of tariffs as of May 1, but since that situation might change, there's some uncertainty. Despite the factors that led to its post-earnings decline, Eli Lilly ...
NEW YORK (AP) — U.S. stocks are rising after President Donald Trump said he was set to announce an agreement on trade with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results